Exploring Developments in IgAN and FSGS
Howard Trachtman, MD, FASN
Richard Lafayette, MD, FACP
Can We Do Better in IgAN?
Jonathan Barratt, PhD
Annette Bruchfeld, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Case-Based Management of AAV
David Jayne, MD
Pinpointing the Top Questions about Biosimilars in Rheumatology
Leonard H. Calabrese, DO
John R. Tesser, MD